In:
PLOS Global Public Health, Public Library of Science (PLoS), Vol. 2, No. 8 ( 2022-8-5), p. e0000658-
Abstract:
SARS-CoV-2 seroprevalence surveys provide critical information to assess the burden of COVID-19, describe population immunity, and guide public health strategies. Early in the pandemic, most of these surveys were conducted within high-income countries, leaving significant knowledge gaps in low-and middle-income (LMI) countries. To address this gap, the U.S. Centers for Disease Control and Prevention (CDC) is supporting serosurveys internationally. We conducted a descriptive analysis of international serosurveys supported by CDC during May 12, 2020–February 28, 2022, using an internal tracker including data on the type of assistance provided, study design, population surveyed, laboratory testing performed, and status of implementation. Since the beginning of the pandemic, CDC has supported 72 serosurveys (77 serosurvey rounds) in 35 LMI countries by providing technical assistance (TA) on epidemiologic, statistical, and laboratory methods, financial assistance (FA), or both. Among these serosurvey rounds, the majority (61%) received both TA and FA from CDC, 30% received TA only, 3% received only FA, and 5% were part of informal reviews. Fifty-four percent of these serosurveys target the general population, 13% sample pregnant women, 7% sample healthcare workers, 7% sample other special populations (internally displaced persons, patients, students, and people living with HIV), and 18% assess multiple or other populations. These studies are in different stages of implementation, ranging from protocol development to dissemination of results. They are conducted under the leadership of local governments, who have ownership over the data, in collaboration with international partners. Thirty-four surveys rounds have completed data collection. CDC TA and FA of SARS-CoV-2 seroprevalence surveys will enhance the knowledge of the COVID-19 pandemic in almost three dozen LMI countries. Support for these surveys should account for current limitations with interpreting results, focusing efforts on prospective cohorts, identifying, and forecasting disease patterns over time, and helping understand antibody kinetics and correlates of protection.
Type of Medium:
Online Resource
ISSN:
2767-3375
DOI:
10.1371/journal.pgph.0000658
DOI:
10.1371/journal.pgph.0000658.g001
DOI:
10.1371/journal.pgph.0000658.t001
DOI:
10.1371/journal.pgph.0000658.t002
DOI:
10.1371/journal.pgph.0000658.s001
DOI:
10.1371/journal.pgph.0000658.s002
DOI:
10.1371/journal.pgph.0000658.s003
DOI:
10.1371/journal.pgph.0000658.s004
DOI:
10.1371/journal.pgph.0000658.r001
DOI:
10.1371/journal.pgph.0000658.r002
DOI:
10.1371/journal.pgph.0000658.r003
DOI:
10.1371/journal.pgph.0000658.r004
DOI:
10.1371/journal.pgph.0000658.r005
DOI:
10.1371/journal.pgph.0000658.r006
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2022
detail.hit.zdb_id:
3101394-6
Bookmarklink
